Alcobra Ltd. (ADHD) Rating Reiterated by Jefferies Group
Alcobra Ltd. (NASDAQ:ADHD)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group in a research note issued to investors on Monday. They presently have a $6.00 target price on the stock, down from their previous target price of $9.00. Jefferies Group’s price target indicates a potential upside of 142.91% from the company’s current price.
Several other research firms have also commented on ADHD. Cantor Fitzgerald restated a “buy” rating and issued a $16.00 price target on shares of Alcobra in a report on Thursday. Goldman Sachs Group Inc. restated a “buy” rating on shares of Alcobra in a report on Thursday, September 1st. Piper Jaffray Cos. restated an “overweight” rating and issued a $10.00 price target on shares of Alcobra in a report on Tuesday, August 30th. Barclays PLC assumed coverage on shares of Alcobra in a report on Monday, August 1st. They issued an “equal weight” rating and a $8.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Alcobra from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $6.47.
Alcobra (NASDAQ:ADHD) traded up 2.227% during mid-day trading on Monday, reaching $2.525. 281,117 shares of the company traded hands. The stock’s market capitalization is $69.59 million. Alcobra has a 52-week low of $1.95 and a 52-week high of $8.78. The firm’s 50-day moving average is $4.69 and its 200 day moving average is $4.51.
Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. On average, equities research analysts expect that Alcobra will post ($0.94) earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the company. Stifel Financial Corp increased its stake in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock worth $278,000 after buying an additional 15,800 shares during the last quarter. Palo Alto Investors LLC increased its stake in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares during the last quarter. VHCP Management LLC increased its stake in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the last quarter. VHCP Management II LLC increased its stake in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the last quarter. Finally, Jefferies Group LLC bought a new stake in Alcobra during the second quarter worth $533,000. 73.69% of the stock is owned by institutional investors and hedge funds.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.